Opin vísindi

A European-Japanese study on peach allergy : IgE to Pru p 7 associates with severity

Show simple item record

dc.contributor.author Kallen, E J J
dc.contributor.author Revers, A
dc.contributor.author Fernández-Rivas, M
dc.contributor.author Asero, R
dc.contributor.author Ballmer-Weber, B
dc.contributor.author Barreales, L
dc.contributor.author Belohlavkova, S
dc.contributor.author de Blay, F
dc.contributor.author Clausen, Michael Valur
dc.contributor.author Dubakiene, R
dc.contributor.author Ebisawa, M
dc.contributor.author Fernández-Perez, C
dc.contributor.author Fritsche, P
dc.contributor.author Fukutomi, Y
dc.contributor.author Gislason, David
dc.contributor.author Hoffmann-Sommergruber, K
dc.contributor.author Jedrzejczak-Czechowicz, M
dc.contributor.author Knulst, A C
dc.contributor.author Kowalski, M L
dc.contributor.author Kralimarkova, T
dc.contributor.author Lidholm, J
dc.contributor.author Metzler, C
dc.contributor.author Mills, E N C
dc.contributor.author Papadopoulos, N G
dc.contributor.author Popov, T A
dc.contributor.author Purohit, A
dc.contributor.author Reig, I
dc.contributor.author Seneviratne, S L
dc.contributor.author Sinaniotis, A
dc.contributor.author Takei, M
dc.contributor.author Versteeg, S A
dc.contributor.author Vassilopoulou, A E
dc.contributor.author Vieths, S
dc.contributor.author Welsing, P M J
dc.contributor.author Zwinderman, A H
dc.contributor.author Le, T M
dc.contributor.author Van Ree, R
dc.date.accessioned 2023-06-29T01:04:40Z
dc.date.available 2023-06-29T01:04:40Z
dc.date.issued 2023-09
dc.identifier.citation Kallen , E J J , Revers , A , Fernández-Rivas , M , Asero , R , Ballmer-Weber , B , Barreales , L , Belohlavkova , S , de Blay , F , Clausen , M V , Dubakiene , R , Ebisawa , M , Fernández-Perez , C , Fritsche , P , Fukutomi , Y , Gislason , D , Hoffmann-Sommergruber , K , Jedrzejczak-Czechowicz , M , Knulst , A C , Kowalski , M L , Kralimarkova , T , Lidholm , J , Metzler , C , Mills , E N C , Papadopoulos , N G , Popov , T A , Purohit , A , Reig , I , Seneviratne , S L , Sinaniotis , A , Takei , M , Versteeg , S A , Vassilopoulou , A E , Vieths , S , Welsing , P M J , Zwinderman , A H , Le , T M & Van Ree , R 2023 , ' A European-Japanese study on peach allergy : IgE to Pru p 7 associates with severity ' , Allergy , vol. 78 , no. 9 , pp. 2497-2509 . https://doi.org/10.1111/all.15783
dc.identifier.issn 0105-4538
dc.identifier.other 155351109
dc.identifier.other 9f34768e-d970-477c-aef3-29dee4b3632d
dc.identifier.other 37334557
dc.identifier.other 85162242014
dc.identifier.other unpaywall: 10.1111/all.15783
dc.identifier.uri https://hdl.handle.net/20.500.11815/4352
dc.description Funding Information: M. Fernández‐Rivas received grants or contracts from Instituto de Salud Carlos III, Spanish Government, Aimmune Therapeutics, Diater, and Novartis; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Aimmune Therapeutics, Ediciones Mayo S.A., Diater, Ga2LEN, HAL Allergy, GSK, MEDSCAPE, NOVARTIS, and EPG Health; is member of the Data Safety Monitoring Board at DBV and advisory board at Aimmune Therapeutics, Novartis, Reacta Healthcare, and SPRIM. B. Ballmer‐Weber received consulting fees from ALK, Allergopharma, Menarini, Sanofi, Novartis, Thermofisher and Aimune and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ALK, Menarini, Sanofi, Novartis, and Thermofisher. F. De Blay received grants or contract from Aimmune, Stallergenes Greer, GSK, ALK, Chiesi, and Regeneron. Y. Fukutomi received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Thermo Fisher Diagnostics KK. K. Hoffmann‐Sommergruber received funding from Danube Allergy Research Cluster funded by the Country of Lower Austria to (P07) KHS; was Member of the EAACI board until 2022/07. J. Lidholm is employee at Thermo Fisher Scientific. E.N.C Mills received grants or has contracts from Food Standards Agency Patterns and prevalence of adult food allergy (FS101174), European Food Safety Authority (ThRAll; allergenicity prediction [with EuroFIR]) and from Innovate (ML for food allergy); has applied for a patent on oral food challenge meal formulations for diagnosis of food allergy; is member of the Advisory Board of Novartis and Advisory Committee on Novel Foods and Processes; and is shareholder of Reacta Healthcare Ltd. N.G. Papadopoulos received grants or contracts from Capricare, Nestle, Numil, Vianex; received consultancy fees from Abbott, Abbvie, Astra Zeneca, GSK, HAL, Medscape, Menarini/Faes Farma, Mylan, Novartis, Nutricia, OM Pharma, and Regeneron/Sanofi. S. Vieths received royalties or licenses from Schattauer Allergologie Handbuch, Elsevier Nahrungsmittelallergien and Intoleranzen and Karger Food Allergy: Molecular Basis and Clinical Practice; support for attending meetings and/or travel as Associate Editor of the Journal of Allergy and Clinical Immunology. R. van Ree received consulting fees from HAL Allergy, Citeq, Angany, Reacta Healthcare, Mission MightyMe, and Ab Enzymes; received payment of honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from HAL Allergy, Thermo Fisher Scientific and ALK; received payment for expert testimony from AB Enzymes; has stock option at Angany. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This work was funded by the European Commission under the 6th Framework Programme through EuroPrevall (FP6‐FOOD‐CT‐2005‐514000), and the 7th Framework Programme iFAAM (grant agreement no. 31214). Funding Information: We thank all the patients for their participation in the study. We would like to thank ALK Abello (Madrid, Spain) for their generous gift of SPT reagents. We thank Angelica Ehrenberg, Jonas Östling and Lars Mattsson (Uppsala) for preparing recombinant Cup s 7 and custom ImmunoCAP tests for this study. We acknowledge the support by the 6th and 7th Framework Programmes of the EU, for EuroPrevall (FP6‐FOOD‐CT‐2005‐514000) and iFAAM (Grant agreement no. 312147), respectively. We thank Alejandro Gonzalo Fernández (Hospital Clinico San Carlos, IdISSC, Madrid) for implementing the FASS in the data set. Publisher Copyright: © 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. Funding Information: M. Fernández‐Rivas received grants or contracts from Instituto de Salud Carlos III, Spanish Government, Aimmune Therapeutics, Diater, and Novartis; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Aimmune Therapeutics, Ediciones Mayo S.A., Diater, Ga2LEN, HAL Allergy, GSK, MEDSCAPE, NOVARTIS, and EPG Health; is member of the Data Safety Monitoring Board at DBV and advisory board at Aimmune Therapeutics, Novartis, Reacta Healthcare, and SPRIM. B. Ballmer‐Weber received consulting fees from ALK, Allergopharma, Menarini, Sanofi, Novartis, Thermofisher and Aimune and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ALK, Menarini, Sanofi, Novartis, and Thermofisher. F. De Blay received grants or contract from Aimmune, Stallergenes Greer, GSK, ALK, Chiesi, and Regeneron. Y. Fukutomi received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Thermo Fisher Diagnostics KK. K. Hoffmann‐Sommergruber received funding from Danube Allergy Research Cluster funded by the Country of Lower Austria to (P07) KHS; was Member of the EAACI board until 2022/07. J. Lidholm is employee at Thermo Fisher Scientific. E.N.C Mills received grants or has contracts from Food Standards Agency Patterns and prevalence of adult food allergy (FS101174), European Food Safety Authority (ThRAll; allergenicity prediction [with EuroFIR]) and from Innovate (ML for food allergy); has applied for a patent on oral food challenge meal formulations for diagnosis of food allergy; is member of the Advisory Board of Novartis and Advisory Committee on Novel Foods and Processes; and is shareholder of Reacta Healthcare Ltd. N.G. Papadopoulos received grants or contracts from Capricare, Nestle, Numil, Vianex; received consultancy fees from Abbott, Abbvie, Astra Zeneca, GSK, HAL, Medscape, Menarini/Faes Farma, Mylan, Novartis, Nutricia, OM Pharma, and Regeneron/Sanofi. S. Vieths received royalties or licenses from Schattauer Allergologie Handbuch, Elsevier Nahrungsmittelallergien and Intoleranzen and Karger Food Allergy: Molecular Basis and Clinical Practice; support for attending meetings and/or travel as Associate Editor of the Journal of Allergy and Clinical Immunology. R. van Ree received consulting fees from HAL Allergy, Citeq, Angany, Reacta Healthcare, Mission MightyMe, and Ab Enzymes; received payment of honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from HAL Allergy, Thermo Fisher Scientific and ALK; received payment for expert testimony from AB Enzymes; has stock option at Angany. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This work was funded by the European Commission under the 6th Framework Programme through EuroPrevall (FP6‐FOOD‐CT‐2005‐514000), and the 7th Framework Programme iFAAM (grant agreement no. 31214). Funding Information: We thank all the patients for their participation in the study. We would like to thank ALK Abello (Madrid, Spain) for their generous gift of SPT reagents. We thank Angelica Ehrenberg, Jonas Östling and Lars Mattsson (Uppsala) for preparing recombinant Cup s 7 and custom ImmunoCAP tests for this study. We acknowledge the support by the 6th and 7th Framework Programmes of the EU, for EuroPrevall (FP6‐FOOD‐CT‐2005‐514000) and iFAAM (Grant agreement no. 312147), respectively. We thank Alejandro Gonzalo Fernández (Hospital Clinico San Carlos, IdISSC, Madrid) for implementing the FASS in the data set. Funding Information: We thank all the patients for their participation in the study. We would like to thank ALK Abello (Madrid, Spain) for their generous gift of SPT reagents. We thank Angelica Ehrenberg, Jonas Östling and Lars Mattsson (Uppsala) for preparing recombinant Cup s 7 and custom ImmunoCAP tests for this study. We acknowledge the support by the 6th and 7th Framework Programmes of the EU, for EuroPrevall (FP6-FOOD-CT-2005-514000) and iFAAM (Grant agreement no. 312147), respectively. We thank Alejandro Gonzalo Fernández (Hospital Clinico San Carlos, IdISSC, Madrid) for implementing the FASS in the data set. Publisher Copyright: © 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
dc.description.abstract BACKGROUND: Pru p 3 and Pru p 7 have been implicated as risk factors for severe peach allergy. This study aimed to establish sensitization patterns to five peach components across Europe and in Japan, to explore their relation to pollen and foods and to predict symptom severity. METHODS: In twelve European (EuroPrevall project) and one Japanese outpatient clinic, a standardized clinical evaluation was conducted in 1231 patients who reported symptoms to peach and/or were sensitized to peach. Specific IgE against Pru p 1, 2, 3, 4 and 7 and against Cup s 7 was measured in 474 of them. Univariable and multivariable Lasso regression was applied to identify combinations of parameters predicting severity. RESULTS: Sensitization to Pru p 3 dominated in Southern Europe but was also quite common in Northern and Central Europe. Sensitization to Pru p 7 was low and variable in the European centers but very dominant in Japan. Severity could be predicted by a model combining age of onset of peach allergy, probable mugwort, Parietaria pollen and latex allergy, and sensitization to Japanese cedar pollen, Pru p 4 and Pru p 7 which resulted in an AUC of 0.73 (95% CI 0.73-0.74). Pru p 3 tended to be a risk factor in South Europe only. CONCLUSIONS: Pru p 7 was confirmed as a significant risk factor for severe peach allergy in Europe and Japan. Combining outcomes from clinical and demographic background with serology resulted in a model that could better predict severity than CRD alone.
dc.format.extent 13
dc.format.extent 7734540
dc.format.extent 2497-2509
dc.language.iso en
dc.relation.ispartofseries Allergy; 78(9)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Barnalæknisfræði
dc.subject Peach allergy
dc.subject prediction
dc.subject Pru p 3
dc.subject Pru p 7
dc.subject severity
dc.subject Allergens
dc.subject Antigens, Plant
dc.subject Humans
dc.subject Immunoglobulin E
dc.subject Plant Proteins
dc.subject Prunus persica/adverse effects
dc.subject Food Hypersensitivity/diagnosis
dc.subject Immunology and Allergy
dc.subject Immunology
dc.title A European-Japanese study on peach allergy : IgE to Pru p 7 associates with severity
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.1111/all.15783
dc.relation.url http://www.scopus.com/inward/record.url?scp=85162242014&partnerID=8YFLogxK
dc.contributor.department Other departments


Files in this item

This item appears in the following Collection(s)

Show simple item record